Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Harvard Bioscience ( (HBIO) ) has shared an update.
On August 8, 2025, Harvard Bioscience, Inc. entered into a Sixth Amendment to its Credit Agreement with Citizens Bank and other lenders. The amendment waives certain defaults and adjusts financial covenants, but raises concerns about the company’s ability to continue operations past December 2025 without securing additional capital or refinancing its debt.
The most recent analyst rating on (HBIO) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
Harvard Bioscience’s overall stock score reflects a mix of financial challenges and strategic opportunities. The most significant factor is the company’s financial performance, which shows areas needing improvement, particularly in profitability and revenue generation. Technical analysis indicates short-term bullish momentum, while valuation remains a concern due to negative earnings. The earnings call and corporate events provide a positive outlook with strong financial discipline and strategic leadership changes, offering potential for future growth.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. operates in the life sciences industry, focusing on providing scientific instruments and solutions for research and drug discovery.
Average Trading Volume: 12,339,670
Technical Sentiment Signal: Sell
Current Market Cap: $23.34M
For a thorough assessment of HBIO stock, go to TipRanks’ Stock Analysis page.